OTraces Inc. Cancer Blood Test Software Technology Tumor Detection, Monitoring and Drug Development October 2018 INVESTOR PRESENTATION
$2.5 million offering to fund final Johns Hopkins validation and launch prostate cancer Active Surveillance blood test in the U.S.
Blinded clinical results to date show 90%+ accuracy for both prostate and breast cancer detection and monitoring. No known direct competition.
Attainment of 90%+ accuracy (predictive power) in a blood test using math/physics-based proteomic noise suppression;
Detection of cytokine activity in the tumor microenvironment (TME) to track tumor status and progression in real time without biopsy.
Noise suppression and the TME as potential blockbuster technologies for diagnostics and drug development
Near Term Commercialization Opportunities and Possible Non-Dilutive Liquidity Events
U.S. launch of Active Surveillance Prostate Cancer Test (pending) – no FDA approval needed ---- funded by current $2.5M raise
Prostate cancer screening test in Canada for accelerated approval – subject to estimated $5-7M in funding to finance clinical trials
Breast cancer patient monitoring LDT in China --- no cFDA approval expected --- subject to estimated $5-8M in additional funding
Sale of exclusive marketing/development rights for multiple potential indications in non-core disease areas or non-core markets.